Renasant Bio Alternatives & Competitors
12 companies similar to Renasant Bio — Transforming the Treatment of ADPKD
Companies similar to Renasant Bio
Rectify Pharma
Developing Positive Functional Modulators (PFMs) to restore and enhance membrane protein f...
Boston, United States
Atorvia Health Technologies
Fearlessly tackling kidney failure
Kanata, Canada
Gain Therapeutics
Unfolding the next generation of allosteric small molecule therapies to meet patient needs...
Bethesda, United States
AZTherapies
Targeting Neuroinflammation: The Common Thread of Neurodegenerative Disease Progression
Boston, United States
Track all Renasant Bio competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Contineum Therapeutics
Pioneering differentiated therapies for the treatment of neuroscience, inflammation and im...
San Diego, United States
Angion
Angion is committed to transforming the treatment paradigm for patients suffering from fib...
United States
Abarceo Pharma AB
Developing the first disease modifying and durable treatment for type 2 and type 1 diabete...
Malmo, Sweden
Photys Therapeutics
Developing novel bifunctional medicines for fine-tuned control of protein post-translation...
Waltham, United States
-logo.jpg "Entero Therapeutics (Nasdaq: ENTO)"){kind=logo}
Entero Therapeutics (Nasdaq: ENTO)
A biopharma company focused on the development of targeted, non-systemic therapies for gas...
Boca Raton, United States
Allyx Therapeutics
Protecting Synapses and Reversing Neurodegeneration
New Haven, United States
Nuevocor
Pioneering novel therapies for untreatable cardiac diseases
Singapore, Singapore
Sionna Therapeutics
Dedicated to delivering therapies that could be transformational for people living with cy...
Boston, United States
About Renasant Bio
Renasant Bio, with its slogan "Transforming the Treatment of ADPKD," is making significant strides in the Biotechnology sector. The company is dedicated to developing disease-modifying oral small molecule treatments specifically for autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of end-st...
Development of small molecule correctors and potentiators, Restoration of PC1/2 protein function, Disease-modifying therapy development for ADPKD
Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), Biopharma researchers, Healthcare providers specializing in renal diseases
Biopharmaceutical, ADPKD Treatment, Disease-Modifying Therapies, Oral Small Molecules, Genetic Disease, End-Stage Renal Failure, Protein Function Restoration, Drug Development, Polycystic Kidney Disease, Biomedical Innovation, Small Molecule Correctors, Small Molecule Potentiators
B2B2C, B2B
Product Sales, Licensing
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Renasant Bio and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Renasant Bio on 9 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
